Question 1

What is Tiziana Life Sciences?

Accepted Answer

Tiziana Life Sciences is a Company.

Question 2

How often does Tiziana Life Sciences appear in global news?

Accepted Answer

Tracked across 7 news events drawn from 43 articles.

Question 3

When was Tiziana Life Sciences first tracked by Ergen?

Accepted Answer

First tracked on Apr 01, 2026.

Question 4

When was Tiziana Life Sciences last mentioned in news?

Accepted Answer

Last active on Jun 25, 2026.

Question 5

What is Tiziana Life Sciences's current news sentiment?

Accepted Answer

Aggregate sentiment score: 48 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Tiziana Life Sciences in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 7 events.

Question 7

What is the most recent event involving Tiziana Life Sciences?

Accepted Answer

Tiziana Life Sciences' Foralumab Preclinical Data (Apr 16, 2026, 6 articles).

Question 8

Who is Tiziana Life Sciences most connected to?

Accepted Answer

Top relationships: Ivor Elrifi, Ivor Elrifi.

Question 9

How did the "Tiziana Life Sciences' Foralumab Preclinical Data" event impact Tiziana Life Sciences?

Accepted Answer

Tiziana Life Sciences announced positive preclinical data for its lead candidate, intranasal foralumab, showing its potential to treat Long COVID neuroinflammation and cognitive dysfunction. This positive data could significantly boost the company's stock price and future prospects.

Question 10

How did the "Tiziana Foralumab na-SPMS Clinical Data" event impact Tiziana Life Sciences?

Accepted Answer

Tiziana Life Sciences announced positive updated clinical data for its lead candidate, intranasal foralumab, in patients with non-active Secondary Progressive Multiple Sclerosis, which could significantly advance its drug development program and potential market position.

Question 11

How did the "Tiziana Doses Last INFORM-MS Patient" event impact Tiziana Life Sciences?

Accepted Answer

Tiziana Life Sciences is the biotechnology company developing intranasal foralumab and is conducting the INFORM-MS Phase 2a clinical trial. The successful dosing of the last patient is a significant milestone for the company, potentially leading to positive future clinical outcomes and increased investor confidence.

Question 12

How did the "Gilead Sciences Acquires Tubulis for $5B" event impact Tiziana Life Sciences?

Accepted Answer

Tiziana Life Sciences exited its minority stake in Tubulis through this sale, representing a strong strategic outcome for its LSP 7 fund and co-investors.

Question 13

How did the "Innovative Molecules Doses First Patient" event impact Tiziana Life Sciences?

Accepted Answer

Tiziana Life Sciences is mentioned through Joachim Rothe, a partner and chairman of Innovative Molecules's advisory board, indicating their involvement and support for the company's strategic direction.

Question 14

How did the "AstronauTx appoints new CMO and VP" event impact Tiziana Life Sciences?

Accepted Answer

Tiziana Life Sciences participated in AstronauTx's Series A financing.

Question 15

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.